US2012251548A1PendingUtilityA1

Treatment of Dermatological Pathologies

48
Assignee: SIMARD JOHNPriority: Apr 1, 2011Filed: Apr 2, 2012Published: Oct 4, 2012
Est. expiryApr 1, 2031(~4.7 yrs left)· nominal 20-yr term from priority
Inventors:John Simard
A61P 29/00A61K 2039/545A61K 2039/505C07K 16/244C07K 2317/21C07K 16/245C07K 2317/76A61K 2039/54A61P 17/00A61K 39/3955
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Skin inflammation in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α.

Claims

exact text as granted — not AI-modified
1 . A method of reducing skin inflammation in a human subject, the method comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of an agent that selectively binds IL-1α effective to reduce skin inflammation in the subject. 
     
     
         2 . The method of  claim 1 , wherein the agent is an anti-IL-1α antibody. 
     
     
         3 . The method of  claim 2 , wherein the anti-IL-1α antibody is a monoclonal antibody. 
     
     
         4 . The method of  claim 3 , wherein the monoclonal antibody is an IgG1. 
     
     
         5 . The method of  claim 3 , wherein the monoclonal antibody comprises a complementarity determining region of MABp1. 
     
     
         6 . The method of  claim 3 , wherein the monoclonal antibody is MABp1. 
     
     
         7 . The method of  claim 1 , wherein the skin inflammation is associated with acne vulgaris. 
     
     
         8 . The method of  claim 1 , wherein the skin inflammation is associated with psoriasis vulgaris.

Join the waitlist — get patent alerts

Track US2012251548A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.